vimarsana.com
Home
Live Updates
AstraZeneca: IMFINZI (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up : vimarsana.com
AstraZeneca: IMFINZI (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up
HIMALAYA Phase III trial exploratory results support the benefit of tremelimumab added to IMFINZI in unresectable liver cancer regardless of etiology Updated results from the TOPAZ-1 Phase III trial
Related Keywords
Paris
,
France General
,
France
,
China
,
Seoul
,
Soult Ukpyolsi
,
South Korea
,
Japan
,
United States
,
Thailand
,
India
,
United Kingdom
,
Cambridge
,
Cambridgeshire
,
Canada
,
America
,
Jessica Mcduell
,
South East Asia
,
Daiichi Sankyo
,
Brendan Mcevoy
,
Gastroenterol Hepatol
,
Susan Galbraith
,
Company Immuno
,
National Comprehensive Cancer Network Inc
,
Seoul National University College Of Medicine
,
Merck Co Inc
,
Company On Twitter Astrazeneca
,
Astrazeneca
,
Division Of Medical Oncology
,
European Society For Medical Oncology
,
European Society
,
Medical Oncology
,
Internal Medicine
,
Seoul National University Hospital
,
Seoul National University College
,
Executive Vice President
,
Response Evaluation Criteria In Solid Tumors
,
Thyroid Disorders
,
Hyperthyroidism Immune Mediated
,
Immune Mediated Nephritis
,
Immune Mediated Dermatology
,
Stevens Johnson Syndrome
,
Prescribing Information
,
South America
,
Rare Diseases
,
Renal Metabolism
,
Aliment Pharmacol
,
Biliary Tract
,
Accessed September
,
Tailored Oncology Treatment
,
Gastroenterol Res
,
Practice Guidelines
,
Comprehensive Cancer Network
,
Rev Gastroenterol
,
Imfinzi
,
Durvalumab
,
Plus
,
Chemotherapy
,
Urther
,
Mproved
,
Verall
,
Survival
,
Benefit
,
Dvanced
,
Miliary
,
Tract
,
Dancer
,
Topaz
,
Hase
,
Trial
,
Educing
,
Risk
,
Death
,
Dditional
,
Follow
,
vimarsana.com © 2020. All Rights Reserved.